{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:17:12Z","timestamp":1793315832920,"version":"4.5.0"},"reference-count":166,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T00:00:00Z","timestamp":1722816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2018-02580"],"award-info":[{"award-number":["2018-02580"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006313","name":"Swedish Childhood Cancer Foundation","doi-asserted-by":"publisher","award":["PR2021-0131"],"award-info":[{"award-number":["PR2021-0131"]}],"id":[{"id":"10.13039\/501100006313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Neuroblastoma (NB), a heterogenous pediatric tumor of the sympathetic nervous system, is the most common and deadly extracranial solid malignancy diagnosed in infants. Numerous efforts have been invested in understanding its origin and in development of novel curative targeted therapies. Here, we summarize the recent advances in the identification of the cell of origin and the genetic alterations occurring during development that contribute to NB. We discuss current treatment regimens, present and future directions for the identification of novel therapeutic metabolic targets, differentiation agents, as well as personalized combinatory therapies as potential approaches for improving the survival and quality of life of children with NB.<\/jats:p>","DOI":"10.1093\/neuonc\/noae152","type":"journal-article","created":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T06:41:00Z","timestamp":1722840060000},"page":"2174-2192","source":"Crossref","is-referenced-by-count":57,"title":["Defining neuroblastoma: From origin to precision medicine"],"prefix":"10.1093","volume":"26","author":[{"given":"Lourdes","family":"Sainero-Alcolado","sequence":"first","affiliation":[{"name":"Department of Microbiology, Tumor and Cell Biology (MTC), Biomedicum B7, Karolinska Institutet , Stockholm SE-17165,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Sj\u00f6berg Bexelius","sequence":"additional","affiliation":[{"name":"Department of Women\u2019s and Children\u2019s Health, Karolinska Institutet , Stockholm SE-17177,","place":["Sweden"]},{"name":"Paediatric Oncology Unit, Astrid Lindgren\u2019s Children Hospital , Solna SE-17164,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Santopolo","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Tumor and Cell Biology (MTC), Biomedicum B7, Karolinska Institutet , Stockholm SE-17165,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Tumor and Cell Biology (MTC), Biomedicum B7, Karolinska Institutet , Stockholm SE-17165,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8097-4750","authenticated-orcid":false,"given":"Judit","family":"Lia\u00f1o-Pons","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Tumor and Cell Biology (MTC), Biomedicum B7, Karolinska Institutet , Stockholm SE-17165,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6376-7792","authenticated-orcid":false,"given":"Marie","family":"Arsenian-Henriksson","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Division of Translational Cancer Research, Lund University , Lund SE-22381,","place":["Sweden"]},{"name":"Department of Microbiology, Tumor and Cell Biology (MTC), Biomedicum B7, Karolinska Institutet , Stockholm SE-17165,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,5]]},"reference":[{"issue":"11","key":"2024121020403990700_CIT0001","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1093\/jnci\/djad115","article-title":"Counts, incidence rates, and trends of pediatric cancer in the United States, 2003-2019","volume":"115","author":"Siegel","year":"2023","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"2024121020403990700_CIT0002","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S1470-2045(17)30186-9","article-title":"International incidence of childhood cancer, 2001-10: a population-based registry study","volume":"18","author":"Steliarova-Foucher","year":"2017","journal-title":"Lancet Oncol."},{"issue":"7696","key":"2024121020403990700_CIT0003","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature25480","article-title":"The landscape of genomic alterations across childhood cancers","volume":"555","author":"Gr\u00f6bner","year":"2018","journal-title":"Nature."},{"issue":"12","key":"2024121020403990700_CIT0004","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1200\/JCO.1988.6.12.1874","article-title":"International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma","volume":"6","author":"Brodeur","year":"1988","journal-title":"J Clin Oncol"},{"issue":"2","key":"2024121020403990700_CIT0005","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00441-017-2761-2","article-title":"Spontaneous regression of neuroblastoma","volume":"372","author":"Brodeur","year":"2018","journal-title":"Cell Tissue Res."},{"issue":"9579","key":"2024121020403990700_CIT0006","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(07)60983-0","article-title":"Neuroblastoma","volume":"369","author":"Maris","year":"2007","journal-title":"Lancet."},{"issue":"9","key":"2024121020403990700_CIT0007","first-page":"114","article-title":"High-risk neuroblastoma treatment review","volume":"5","author":"Smith","year":"2018","journal-title":"Children (Basel)"},{"issue":"8","key":"2024121020403990700_CIT0008","first-page":"107","article-title":"Late effects and survivorship issues in patients with neuroblastoma","volume":"5","author":"Friedman","year":"2018","journal-title":"Children (Basel)"},{"key":"2024121020403990700_CIT0009","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.semcdb.2022.06.008","article-title":"On the evolutionary origins and regionalization of the neural crest","volume":"138","author":"Rothstein","year":"2023","journal-title":"Semin Cell Dev Biol"},{"issue":"6","key":"2024121020403990700_CIT0010","doi-asserted-by":"crossref","first-page":"eabd3311","DOI":"10.1126\/sciadv.abd3311","article-title":"Tumor to normal single-cell mRNA comparisons reveal a pan-neuroblastoma cancer cell","volume":"7","author":"Kildisiute","year":"2021","journal-title":"Sci Adv."},{"issue":"1","key":"2024121020403990700_CIT0011","doi-asserted-by":"crossref","first-page":"5309","DOI":"10.1038\/s41467-021-24870-7","article-title":"Single-nuclei transcriptomes from human adrenal gland reveal distinct cellular identities of low and high-risk neuroblastoma tumors","volume":"12","author":"Bedoya-Reina","year":"2021","journal-title":"Nat Commun."},{"issue":"5","key":"2024121020403990700_CIT0012","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/s41588-021-00806-1","article-title":"Single-cell transcriptomic analyses provide insights into the developmental origins of neuroblastoma","volume":"53","author":"Jansky","year":"2021","journal-title":"Nat Genet."},{"issue":"5","key":"2024121020403990700_CIT0013","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.ccell.2020.08.014","article-title":"Single-cell characterization of malignant phenotypes and developmental trajectories of adrenal neuroblastoma","volume":"38","author":"Dong","year":"2020","journal-title":"Cancer Cell"},{"issue":"5","key":"2024121020403990700_CIT0014","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/s41588-021-00818-x","article-title":"Single-cell transcriptomics of human embryos identifies multiple sympathoblast lineages with potential implications for neuroblastoma origin","volume":"53","author":"Kameneva","year":"2021","journal-title":"Nat Genet."},{"issue":"6","key":"2024121020403990700_CIT0015","doi-asserted-by":"crossref","first-page":"100657","DOI":"10.1016\/j.xcrm.2022.100657","article-title":"The immune cell atlas of human neuroblastoma","volume":"3","author":"Verhoeven","year":"2022","journal-title":"Cell Rep Med"},{"issue":"8","key":"2024121020403990700_CIT0016","doi-asserted-by":"crossref","first-page":"e004807","DOI":"10.1136\/jitc-2022-004807","article-title":"Single-cell transcriptomics reveals shared immunosuppressive landscapes of mouse and human neuroblastoma","volume":"10","author":"Costa","year":"2022","journal-title":"J ImmunoTher Cancer."},{"issue":"1","key":"2024121020403990700_CIT0017","doi-asserted-by":"crossref","first-page":"111455","DOI":"10.1016\/j.celrep.2022.111455","article-title":"Single-cell profiling of peripheral neuroblastic tumors identifies an aggressive transitional state that bridges an adrenergic-mesenchymal trajectory","volume":"41","author":"Yuan","year":"2022","journal-title":"Cell Rep"},{"issue":"6","key":"2024121020403990700_CIT0018","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/j.gendis.2021.12.020","article-title":"Single-cell landscape analysis reveals distinct regression trajectories and novel prognostic biomarkers in primary neuroblastoma","volume":"9","author":"Liu","year":"2022","journal-title":"Genes & Dis"},{"issue":"1","key":"2024121020403990700_CIT0019","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1038\/s41467-023-38239-5","article-title":"Reversible transitions between noradrenergic and mesenchymal tumor identities define cell plasticity in neuroblastoma","volume":"14","author":"Thirant","year":"2023","journal-title":"Nat Commun."},{"issue":"6346","key":"2024121020403990700_CIT0020","doi-asserted-by":"crossref","first-page":"eaal3753","DOI":"10.1126\/science.aal3753","article-title":"Multipotent peripheral glial cells generate neuroendocrine cells of the adrenal medulla","volume":"357","author":"Furlan","year":"2017","journal-title":"Science."},{"issue":"8","key":"2024121020403990700_CIT0021","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/ng.3899","article-title":"Neuroblastoma is composed of two super-enhancer-associated differentiation states","volume":"49","author":"van Groningen","year":"2017","journal-title":"Nat Genet."},{"issue":"4","key":"2024121020403990700_CIT0022","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/s41588-023-01332-y","article-title":"Neuroblastoma arises in early fetal development and its evolutionary duration predicts outcome","volume":"55","author":"K\u00f6rber","year":"2023","journal-title":"Nat Genet."},{"issue":"6","key":"2024121020403990700_CIT0023","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/s41588-023-01395-x","article-title":"Clonal evolution during metastatic spread in high-risk neuroblastoma","volume":"55","author":"Gundem","year":"2023","journal-title":"Nat Genet."},{"issue":"8","key":"2024121020403990700_CIT0024","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1200\/JCO.1993.11.8.1466","article-title":"Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment","volume":"11","author":"Brodeur","year":"1993","journal-title":"J Clin Oncol"},{"issue":"9","key":"2024121020403990700_CIT0025","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1200\/JCO.2000.18.9.1888","article-title":"Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a children\u2019s cancer group study","volume":"18","author":"Maris","year":"2000","journal-title":"J Clin Oncol."},{"issue":"25","key":"2024121020403990700_CIT0026","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1056\/NEJM199906243402504","article-title":"Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma","volume":"340","author":"Bown","year":"1999","journal-title":"N Engl J Med."},{"issue":"January\u2013December","key":"2024121020403990700_CIT0027","first-page":"419","article-title":"Chromosome 1p and 11q deletions and outcome in neuroblastoma\u2014a critical review","volume":"2","author":"Komotar","year":"2008","journal-title":"Clin Med Oncol"},{"issue":"2","key":"2024121020403990700_CIT0028","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/(SICI)1097-0142(19990715)86:2<364::AID-CNCR21>3.0.CO;2-7","article-title":"The international neuroblastoma pathology classification (the Shimada system)","volume":"86","author":"Shimada","year":"1999","journal-title":"Cancer."},{"issue":"2","key":"2024121020403990700_CIT0029","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.2008.16.6785","article-title":"The International Neuroblastoma Risk Group (INRG) classification system: an INRG task force report","volume":"27","author":"Cohn","year":"2009","journal-title":"J Clin Oncol."},{"issue":"1","key":"2024121020403990700_CIT0030","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3390\/biom12010079","article-title":"Genetic and histopathological heterogeneity of neuroblastoma and precision therapeutic approaches for extremely unfavorable histology subgroups","volume":"12","author":"Shimada","year":"2022","journal-title":"Biomolecules."},{"key":"2024121020403990700_CIT0031","volume-title":"Neuroblastoma Treatment (PDQ\u00ae)\u2013Health Professional Version","author":"National Cancer Institute"},{"issue":"4","key":"2024121020403990700_CIT0032","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/SLA.0b013e31826cbbbd","article-title":"A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a children\u2019s oncology group study","volume":"256","author":"Nuchtern","year":"2012","journal-title":"Ann Surg."},{"issue":"3","key":"2024121020403990700_CIT0033","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1200\/JCO.2000.18.3.477","article-title":"Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a children\u2019s cancer group study","volume":"18","author":"Nickerson","year":"2000","journal-title":"J Clin Oncol."},{"issue":"8","key":"2024121020403990700_CIT0034","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1158\/1055-9965.EPI-05-0066","article-title":"Increased risk of cancer among siblings of long-term childhood cancer survivors: a report from the childhood cancer survivor study","volume":"14","author":"Friedman","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"issue":"1","key":"2024121020403990700_CIT0035","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/cncr.29706","article-title":"Advances in the translational genomics of neuroblastoma: from improving risk stratification and revealing novel biology to identifying actionable genomic alterations","volume":"122","author":"Bosse","year":"2016","journal-title":"Cancer."},{"issue":"12","key":"2024121020403990700_CIT0036","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1038\/ng.3438","article-title":"TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors","volume":"47","author":"Valentijn","year":"2015","journal-title":"Nat Genet."},{"issue":"10","key":"2024121020403990700_CIT0037","doi-asserted-by":"crossref","first-page":"a014415","DOI":"10.1101\/cshperspect.a014415","article-title":"Neuroblastoma and MYCN","volume":"3","author":"Huang","year":"2013","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"3","key":"2024121020403990700_CIT0038","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/ng.2529","article-title":"The genetic landscape of high-risk neuroblastoma","volume":"45","author":"Pugh","year":"2013","journal-title":"Nat Genet."},{"key":"2024121020403990700_CIT0039","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1146\/annurev.cellbio.16.1.653","article-title":"The Myc\/Max\/Mad network and the transcriptional control of cell behavior","volume":"16","author":"Grandori","year":"2000","journal-title":"Annu Rev Cell Dev Biol."},{"issue":"624079","key":"2024121020403990700_CIT0040","first-page":"1","article-title":"MYCN function in neuroblastoma development","volume":"10","author":"Otte","year":"2020","journal-title":"Front Oncol."},{"issue":"3","key":"2024121020403990700_CIT0041","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1158\/2159-8290.CD-17-0993","article-title":"MYC drives a subset of high-risk pediatric neuroblastomas and is activated through mechanisms including enhancer hijacking and focal enhancer amplification","volume":"8","author":"Zimmerman","year":"2018","journal-title":"Cancer Discov"},{"issue":"8","key":"2024121020403990700_CIT0042","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1093\/jjco\/hyaa097","article-title":"De novo evolved gene product NCYM in the pathogenesis and clinical outcome of human neuroblastomas and other cancers","volume":"50","author":"Suenaga","year":"2020","journal-title":"Jpn J Clin Oncol."},{"issue":"623679","key":"2024121020403990700_CIT0043","first-page":"1","article-title":"Targeting MYCN in pediatric and adult cancers","volume":"10","author":"Liu","year":"2020","journal-title":"Front Oncol."},{"issue":"3","key":"2024121020403990700_CIT0044","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/s41591-024-02805-1","article-title":"MYC targeting by OMO-103 in solid tumors: a phase 1 trial","volume":"30","author":"Garralda","year":"2024","journal-title":"Nat Med."},{"issue":"1","key":"2024121020403990700_CIT0045","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/s41467-018-03512-5","article-title":"Glycogen synthase kinase 3 controls migration of the neural crest lineage in mouse and Xenopus","volume":"9","author":"Gonzalez Malagon","year":"2018","journal-title":"Nat Commun."},{"issue":"9","key":"2024121020403990700_CIT0046","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.18632\/oncotarget.1883","article-title":"Activated Alk triggers prolonged neurogenesis and Ret upregulation providing a therapeutic target in ALK-mutated neuroblastoma","volume":"5","author":"Cazes","year":"2014","journal-title":"Oncotarget"},{"issue":"7215","key":"2024121020403990700_CIT0047","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1038\/nature07261","article-title":"Identification of ALK as a major familial neuroblastoma predisposition gene","volume":"455","author":"Moss\u00e9","year":"2008","journal-title":"Nature."},{"issue":"22","key":"2024121020403990700_CIT0048","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.1158\/1078-0432.CCR-16-0569","article-title":"The potent ALK inhibitor Brigatinib (AP26113) overcomes mechanisms of resistance to first- and second-generation ALK inhibitors in preclinical models","volume":"22","author":"Zhang","year":"2016","journal-title":"Clin Cancer Res."},{"issue":"5","key":"2024121020403990700_CIT0049","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1038\/s41591-023-02297-5","article-title":"Lorlatinib with or without chemotherapy in ALK-driven refractory\/relapsed neuroblastoma: phase 1 trial results","volume":"29","author":"Goldsmith","year":"2023","journal-title":"Nat Med."},{"issue":"8","key":"2024121020403990700_CIT0050","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1038\/s41416-023-02208-y","article-title":"Genomic ALK alterations in primary and relapsed neuroblastoma","volume":"128","author":"Rosswog","year":"2023","journal-title":"Br J Cancer."},{"issue":"5","key":"2024121020403990700_CIT0051","doi-asserted-by":"crossref","first-page":"e30261","DOI":"10.1002\/pbc.30261","article-title":"Combined analysis of PHOX2B at two time points and its value for further risk stratification in high-risk neuroblastoma","volume":"70","author":"Yue","year":"2023","journal-title":"Pediatr Blood Cancer."},{"issue":"6734","key":"2024121020403990700_CIT0052","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/20700","article-title":"The homeobox gene Phox2b is essential for the development of autonomic neural crest derivatives","volume":"399","author":"Pattyn","year":"1999","journal-title":"Nature."},{"issue":"10","key":"2024121020403990700_CIT0053","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1001\/jama.2012.228","article-title":"Association of age at diagnosis and genetic mutations in patients with neuroblastoma","volume":"307","author":"Cheung","year":"2012","journal-title":"JAMA."},{"issue":"102971","key":"2024121020403990700_CIT0054","first-page":"1","article-title":"Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastoma","volume":"59","author":"George","year":"2020","journal-title":"EBioMedicine"},{"issue":"1","key":"2024121020403990700_CIT0055","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/s41467-020-14682-6","article-title":"MYCN amplification and ATRX mutations are incompatible in neuroblastoma","volume":"11","author":"Zeineldin","year":"2020","journal-title":"Nat Commun."},{"issue":"1","key":"2024121020403990700_CIT0056","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/s41467-021-21247-8","article-title":"Alternative lengthening of telomeres in childhood neuroblastoma from genome to proteome","volume":"12","author":"Hartlieb","year":"2021","journal-title":"Nat Commun."},{"issue":"17","key":"2024121020403990700_CIT0057","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.4161\/cc.10.17.17118","article-title":"Crosstalk between MYCN and MDM2-p53 signal pathways regulates tumor cell growth and apoptosis in neuroblastoma","volume":"10","author":"He","year":"2011","journal-title":"Cell Cycle"},{"issue":"6419","key":"2024121020403990700_CIT0058","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1126\/science.aat6768","article-title":"A mechanistic classification of clinical phenotypes in neuroblastoma","volume":"362","author":"Ackermann","year":"2018","journal-title":"Science."},{"issue":"17","key":"2024121020403990700_CIT0059","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1158\/0008-5472.CAN-22-0671","article-title":"FOXR2 is an epigenetically regulated pan-cancer oncogene that activates ETS transcriptional circuits","volume":"82","author":"Tsai","year":"2022","journal-title":"Cancer Res."},{"issue":"29","key":"2024121020403990700_CIT0060","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1200\/JCO.20.02540","article-title":"FOXR2 stabilizes MYCN protein and identifies non-MYCN-amplified neuroblastoma patients with unfavorable outcome","volume":"39","author":"Schmitt-Hoffner","year":"2021","journal-title":"J Clin Oncol."},{"issue":"18","key":"2024121020403990700_CIT0061","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1016\/j.neuron.2022.07.012","article-title":"Neuroblastoma: when differentiation goes awry","volume":"110","author":"Zeineldin","year":"2022","journal-title":"Neuron."},{"issue":"4","key":"2024121020403990700_CIT0062","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/SLA.0b013e31826cbbbd","article-title":"A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children\u2019s Oncology Group study","volume":"256","author":"Nuchtern","year":"2012","journal-title":"Ann Surg."},{"issue":"25","key":"2024121020403990700_CIT0063","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1200\/JCO.19.03117","article-title":"Influence of surgical excision on the survival of patients with stage 4 high-risk neuroblastoma: a report from the HR-NBL1\/SIOPEN study","volume":"38","author":"Holmes","year":"2020","journal-title":"J Clin Oncol."},{"issue":"6","key":"2024121020403990700_CIT0064","doi-asserted-by":"crossref","first-page":"490.e1","DOI":"10.1016\/j.jtct.2021.03.006","article-title":"Myeloablative busulfan\/melphalan consolidation following induction chemotherapy for patients with newly diagnosed high-risk neuroblastoma: children\u2019s oncology group trial ANBL12P1","volume":"27","author":"Granger","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"23","key":"2024121020403990700_CIT0065","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1200\/JCO.20.03144","article-title":"Randomized trial of two induction therapy regimens for high-risk neuroblastoma: HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group Study","volume":"39","author":"Garaventa","year":"2021","journal-title":"J Clin Oncol"},{"issue":"21","key":"2024121020403990700_CIT0066","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1200\/JCO.2009.27.3524","article-title":"Randomized trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the European HR-NBL1\/SIOPEN study","volume":"28","author":"Ladenstein","year":"2010","journal-title":"J Clin Oncol."},{"issue":"8","key":"2024121020403990700_CIT0067","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1001\/jama.2019.11642","article-title":"Effect of tandem autologous stem cell transplant vs single transplant on event-free survival in patients with high-risk neuroblastoma: a randomized clinical trial","volume":"322","author":"Park","year":"2019","journal-title":"JAMA."},{"issue":"Suppl 2","key":"2024121020403990700_CIT0068","doi-asserted-by":"crossref","first-page":"e28473","DOI":"10.1002\/pbc.28473","article-title":"Neuroblastoma","volume":"68","author":"Chung","year":"2021","journal-title":"Pediatr Blood Cancer."},{"issue":"12","key":"2024121020403990700_CIT0069","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S1470-2045(18)30578-3","article-title":"Interleukin 2 with anti-GD2 antibody ch14.18\/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1\/SIOPEN): a multicentre, randomised, phase 3 trial","volume":"19","author":"Ladenstein","year":"2018","journal-title":"Lancet Oncol."},{"issue":"34","key":"2024121020403990700_CIT0070","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1200\/JCO.19.00919","article-title":"Maintaining outstanding outcomes using response- and biology-based therapy for intermediate-risk neuroblastoma: a report from the children\u2019s oncology group study ANBL0531","volume":"37","author":"Twist","year":"2019","journal-title":"J Clin Oncol."},{"issue":"1","key":"2024121020403990700_CIT0071","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.canlet.2015.11.017","article-title":"More than the genes, the tumor microenvironment in neuroblastoma","volume":"380","author":"Borriello","year":"2016","journal-title":"Cancer Lett."},{"issue":"2","key":"2024121020403990700_CIT0072","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1006\/excr.2001.5463","article-title":"Effects of collagen IV on neuroblastoma cell matrix-related functions","volume":"274","author":"Tzinia","year":"2002","journal-title":"Exp Cell Res."},{"issue":"4","key":"2024121020403990700_CIT0073","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/bjc.2016.210","article-title":"Extracellular matrix composition defines an ultra-high-risk group of neuroblastoma within the high-risk patient cohort","volume":"115","author":"Tadeo","year":"2016","journal-title":"Br J Cancer."},{"issue":"10","key":"2024121020403990700_CIT0074","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.3390\/cancers12102912","article-title":"The tumor microenvironment in neuroblastoma: new players, new mechanisms of interaction and new perspectives","volume":"12","author":"Blavier","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"24","key":"2024121020403990700_CIT0075","first-page":"7357","article-title":"SPARC is a key schwannian-derived inhibitor controlling neuroblastoma tumor angiogenesis","volume":"62","author":"Chlenski","year":"2002","journal-title":"Cancer Res."},{"issue":"6","key":"2024121020403990700_CIT0076","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/1096-911X(20001201)35:6<590::AID-MPO21>3.0.CO;2-O","article-title":"Schwann cell-conditioned medium inhibits angiogenesis in vitro and in vivo","volume":"35","author":"Huang","year":"2000","journal-title":"Med Pediatr Oncol."},{"issue":"2","key":"2024121020403990700_CIT0077","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1089\/scd.2020.0142","article-title":"Mesenchymal stromal cells in neuroblastoma: exploring crosstalk and therapeutic implications","volume":"30","author":"Hochheuser","year":"2021","journal-title":"Stem Cells Dev."},{"issue":"10","key":"2024121020403990700_CIT0078","doi-asserted-by":"crossref","first-page":"7021","DOI":"10.1073\/pnas.102660199","article-title":"Hypoxia alters gene expression in human neuroblastoma cells toward an immature and neural crest-like phenotype","volume":"99","author":"J\u00f6gi","year":"2002","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"1","key":"2024121020403990700_CIT0079","doi-asserted-by":"crossref","first-page":"1597614","DOI":"10.1080\/20013078.2019.1597614","article-title":"Exosomes from N-Myc amplified neuroblastoma cells induce migration and confer chemoresistance to non-N-Myc amplified cells: implications of intra-tumour heterogeneity","volume":"8","author":"Fonseka","year":"2019","journal-title":"J Extracell Vesicles"},{"issue":"November 22","key":"2024121020403990700_CIT0080","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.isci.2019.10.020","article-title":"MYCN-enhanced oxidative and glycolytic metabolism reveals vulnerabilities for targeting neuroblastoma","volume":"21","author":"Oliynyk","year":"2019","journal-title":"iScience"},{"issue":"24","key":"2024121020403990700_CIT0081","doi-asserted-by":"crossref","first-page":"10351","DOI":"10.1158\/0008-5472.CAN-10-0740","article-title":"Combinatorial regulation of neuroblastoma tumor progression by N-Myc and hypoxia inducible factor HIF-1alpha","volume":"70","author":"Qing","year":"2010","journal-title":"Cancer Res."},{"issue":"12","key":"2024121020403990700_CIT0082","doi-asserted-by":"crossref","first-page":"e10835","DOI":"10.15252\/emmm.201910835","article-title":"Therapeutic targeting of circ-CUX1\/EWSR1\/MAZ axis inhibits glycolysis and neuroblastoma progression","volume":"11","author":"Li","year":"2019","journal-title":"EMBO Mol Med."},{"issue":"16","key":"2024121020403990700_CIT0083","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1038\/onc.2015.264","article-title":"BIRC5\/Survivin as a target for glycolysis inhibition in high-stage neuroblastoma","volume":"35","author":"Hagenbuchner","year":"2016","journal-title":"Oncogene."},{"issue":"1","key":"2024121020403990700_CIT0084","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1186\/s12935-021-02330-y","article-title":"Antitumor effects of the small molecule DMAMCL in neuroblastoma via suppressing aerobic glycolysis and targeting PFKL","volume":"21","author":"Zhang","year":"2021","journal-title":"Cancer Cell Int"},{"issue":"1","key":"2024121020403990700_CIT0085","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10637-010-9551-y","article-title":"The combination of the novel glycolysis inhibitor 3-BrOP and rapamycin is effective against neuroblastoma","volume":"30","author":"Levy","year":"2012","journal-title":"Invest New Drugs."},{"issue":"17","key":"2024121020403990700_CIT0086","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1158\/0008-5472.CAN-20-2153","article-title":"Metabolic enzyme DLST promotes tumor aggression and reveals a vulnerability to OXPHOS inhibition in high-risk neuroblastoma","volume":"81","author":"Anderson","year":"2021","journal-title":"Cancer Res."},{"issue":"113032","key":"2024121020403990700_CIT0087","first-page":"1","article-title":"Reversing the HDAC-inhibitor mediated metabolic escape in MYCN-amplified neuroblastoma","volume":"150","author":"Bishayee","year":"2022","journal-title":"Biomed Pharmacother."},{"issue":"13","key":"2024121020403990700_CIT0088","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1016\/j.celrep.2017.12.002","article-title":"Oncogenic MYC activates a feedforward regulatory loop promoting essential amino acid metabolism and tumorigenesis","volume":"21","author":"Yue","year":"2017","journal-title":"Cell Rep"},{"issue":"6","key":"2024121020403990700_CIT0089","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/00000658-199312000-00004","article-title":"Glutamine and cancer","volume":"218","author":"Souba","year":"1993","journal-title":"Ann Surg."},{"issue":"5","key":"2024121020403990700_CIT0090","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ccr.2012.09.021","article-title":"ATF4 regulates MYC-mediated neuroblastoma cell death upon glutamine deprivation","volume":"22","author":"Qing","year":"2012","journal-title":"Cancer Cell"},{"issue":"1","key":"2024121020403990700_CIT0091","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/path.4429","article-title":"ATF4 and N-Myc coordinate glutamine metabolism in MYCN-amplified neuroblastoma cells through ASCT2 activation","volume":"235","author":"Ren","year":"2015","journal-title":"J Pathol."},{"issue":"38","key":"2024121020403990700_CIT0092","doi-asserted-by":"crossref","first-page":"40655","DOI":"10.18632\/oncotarget.5821","article-title":"Myc promotes glutaminolysis in human neuroblastoma through direct activation of glutaminase 2","volume":"6","author":"Xiao","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"2024121020403990700_CIT0093","doi-asserted-by":"crossref","first-page":"7157","DOI":"10.1038\/s41598-020-64040-1","article-title":"N-Myc-induced metabolic rewiring creates novel therapeutic vulnerabilities in neuroblastoma","volume":"10","author":"Tjaden","year":"2020","journal-title":"Sci Rep."},{"issue":"15","key":"2024121020403990700_CIT0094","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1158\/0008-5472.CAN-18-3541","article-title":"Metabolic reprogramming by MYCN confers dependence on the serine-glycine-one-carbon biosynthetic pathway","volume":"79","author":"Xia","year":"2019","journal-title":"Cancer Res."},{"issue":"2","key":"2024121020403990700_CIT0095","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/s41419-024-06490-3","article-title":"MTHFD1 regulates the NADPH redox homeostasis in MYCN-amplified neuroblastoma","volume":"15","author":"Guan","year":"2024","journal-title":"Cell Death Dis."},{"issue":"9","key":"2024121020403990700_CIT0096","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/s41419-021-04120-w","article-title":"Therapeutic targeting of both dihydroorotate dehydrogenase and nucleoside transport in MYCN-amplified neuroblastoma","volume":"12","author":"Yu","year":"2021","journal-title":"Cell Death Dis."},{"issue":"17","key":"2024121020403990700_CIT0097","doi-asserted-by":"crossref","first-page":"e153836","DOI":"10.1172\/jci.insight.153836","article-title":"DHODH is an independent prognostic marker and potent therapeutic target in neuroblastoma","volume":"7","author":"Olsen","year":"2022","journal-title":"JCI Insight"},{"issue":"25","key":"2024121020403990700_CIT0098","doi-asserted-by":"crossref","first-page":"10258","DOI":"10.1073\/pnas.1222404110","article-title":"MYC inhibition induces metabolic changes leading to accumulation of lipid droplets in tumor cells","volume":"110","author":"Zirath","year":"2013","journal-title":"PNAS"},{"issue":"1","key":"2024121020403990700_CIT0099","doi-asserted-by":"crossref","first-page":"3728","DOI":"10.1038\/s41467-022-31331-2","article-title":"MYCN-driven fatty acid uptake is a metabolic vulnerability in neuroblastoma","volume":"13","author":"Tao","year":"2022","journal-title":"Nat Commun."},{"issue":"11","key":"2024121020403990700_CIT0100","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/nrc.2016.89","article-title":"The multifaceted roles of fatty acid synthesis in cancer","volume":"16","author":"R\u00f6hrig","year":"2016","journal-title":"Nat Rev Cancer."},{"issue":"2","key":"2024121020403990700_CIT0101","doi-asserted-by":"crossref","first-page":"102128","DOI":"10.1016\/j.isci.2021.102128","article-title":"Inhibition of fatty acid synthesis induces differentiation and reduces tumor burden in childhood neuroblastoma","volume":"24","author":"Ruiz-P\u00e9rez","year":"2021","journal-title":"iScience"},{"issue":"4","key":"2024121020403990700_CIT0102","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s42255-020-0195-8","article-title":"Identifying strategies to target the metabolic flexibility of tumours","volume":"2","author":"M\u00e9ndez-Lucas","year":"2020","journal-title":"Nat Metab."},{"issue":"7","key":"2024121020403990700_CIT0103","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/s41418-022-01022-y","article-title":"Targeting mitochondrial metabolism for precision medicine in cancer","volume":"29","author":"Sainero-Alcolado","year":"2022","journal-title":"Cell Death Differ."},{"issue":"47","key":"2024121020403990700_CIT0104","doi-asserted-by":"crossref","first-page":"16659","DOI":"10.1073\/pnas.0407643101","article-title":"Histone deacetylase inhibition-mediated neuronal differentiation of multipotent adult neural progenitor cells","volume":"101","author":"Hsieh","year":"2004","journal-title":"Proc Natl Acad Sci USA."},{"issue":"4","key":"2024121020403990700_CIT0105","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s43018-022-00355-4","article-title":"MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis","volume":"3","author":"Alborzinia","year":"2022","journal-title":"Nat Cancer"},{"issue":"10","key":"2024121020403990700_CIT0106","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1002\/pbc.25594","article-title":"Pilot study of intravenous melphalan combined with continuous infusion L-S,R-buthionine sulfoximine for children with recurrent neuroblastoma","volume":"62","author":"Anderson","year":"2015","journal-title":"Pediatr Blood Cancer."},{"issue":"7998","key":"2024121020403990700_CIT0107","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/s41586-023-06878-9","article-title":"7-Dehydrocholesterol is an endogenous suppressor of ferroptosis","volume":"626","author":"Freitas","year":"2024","journal-title":"Nature."},{"issue":"1","key":"2024121020403990700_CIT0108","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13046-022-02281-w","article-title":"Recent advances in the developmental origin of neuroblastoma: an overview","volume":"41","author":"Ponzoni","year":"2022","journal-title":"J Exp Clin Cancer Res."},{"issue":"8","key":"2024121020403990700_CIT0109","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/s43018-022-00405-x","article-title":"Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1","volume":"3","author":"Mabe","year":"2022","journal-title":"Nat Cancer"},{"issue":"43","key":"2024121020403990700_CIT0110","doi-asserted-by":"crossref","first-page":"eabe0834","DOI":"10.1126\/sciadv.abe0834","article-title":"Retinoic acid rewires the adrenergic core regulatory circuitry of childhood neuroblastoma","volume":"7","author":"Zimmerman","year":"2024","journal-title":"Sci Adv."},{"issue":"19","key":"2024121020403990700_CIT0111","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1016\/j.devcel.2023.08.028","article-title":"Palbociclib releases the latent differentiation capacity of neuroblastoma cells","volume":"58","author":"Ferguson","year":"2023","journal-title":"Dev Cell."},{"issue":"2","key":"2024121020403990700_CIT0112","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.3390\/ijms25021047","article-title":"Temporal quantitative proteomic and phosphoproteomic profiling of SH-SY5Y and IMR-32 neuroblastoma cells during all-trans-retinoic acid-induced neuronal differentiation","volume":"25","author":"Leung","year":"2024","journal-title":"Int J Mol Sci ."},{"issue":"3","key":"2024121020403990700_CIT0113","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/sj.bjc.6603554","article-title":"Pharmacokinetics and metabolism of 13-cis-retinoic acid (isotretinoin) in children with high-risk neuroblastoma \u2013 a study of the United Kingdom Children\u2019s Cancer Study Group","volume":"96","author":"Veal","year":"2007","journal-title":"Br J Cancer."},{"issue":"1","key":"2024121020403990700_CIT0114","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/1096-911X(20010101)36:1<127::AID-MPO1030>3.0.CO;2-B","article-title":"The vitamin A analogues: 13-cis retinoic acid, 9-cis retinoic acid, and Ro 13-6307 inhibit neuroblastoma tumour growth in vivo","volume":"36","author":"Ponthan","year":"2001","journal-title":"Med Pediatr Oncol."},{"issue":"3","key":"2024121020403990700_CIT0115","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3390\/jpm11030211","article-title":"Differentiating neuroblastoma: a systematic review of the retinoic acid, its derivatives, and synergistic interactions","volume":"11","author":"Bayeva","year":"2021","journal-title":"J Pers Med"},{"issue":"7","key":"2024121020403990700_CIT0116","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1200\/JCO.2007.13.8925","article-title":"Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children\u2019s oncology group study","volume":"27","author":"Matthay","year":"2009","journal-title":"J Clin Oncol."},{"issue":"1","key":"2024121020403990700_CIT0117","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1186\/s12885-018-4966-5","article-title":"Traffic lights for retinoids in oncology: molecular markers of retinoid resistance and sensitivity and their use in the management of cancer differentiation therapy","volume":"18","author":"Dobrotkova","year":"2018","journal-title":"BMC Cancer"},{"issue":"1","key":"2024121020403990700_CIT0118","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/s13046-022-02399-x","article-title":"Expression and activation of nuclear hormone receptors result in neuronal differentiation and favorable prognosis in neuroblastoma","volume":"41","author":"Sainero-Alcolado","year":"2022","journal-title":"J Exp Clin Cancer Res."},{"issue":"9","key":"2024121020403990700_CIT0119","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1054\/bjoc.2000.1425","article-title":"A randomized trial of 13-Cis retinoic acid in children with advanced neuroblastoma after high-dose therapy","volume":"83","author":"Kohler","year":"2000","journal-title":"Br J Cancer."},{"issue":"8","key":"2024121020403990700_CIT0120","doi-asserted-by":"crossref","first-page":"707","DOI":"10.3390\/pharmaceutics12080707","article-title":"Current trends in ATRA delivery for cancer therapy","volume":"12","author":"Giuli","year":"2020","journal-title":"Pharmaceutics"},{"issue":"6001","key":"2024121020403990700_CIT0121","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/313404a0","article-title":"Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma","volume":"313","author":"Thiele","year":"1985","journal-title":"Nature."},{"issue":"3","key":"2024121020403990700_CIT0122","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1158\/2159-8290.CD-12-0418","article-title":"Targeting MYCN in neuroblastoma by BET Bromodomain inhibition","volume":"3","author":"Puissant","year":"2013","journal-title":"Cancer Discov"},{"issue":"3","key":"2024121020403990700_CIT0123","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.surg.2015.04.017","article-title":"Bromodomain and extraterminal inhibition blocks tumor progression and promotes differentiation in neuroblastoma","volume":"158","author":"Lee","year":"2015","journal-title":"Surgery."},{"issue":"621093","key":"2024121020403990700_CIT0124","first-page":"1","article-title":"Safety and efficacy of bromodomain and extra-terminal inhibitors for the treatment of hematological malignancies and solid tumors: a systematic study of clinical trials","volume":"11","author":"Sun","year":"2021","journal-title":"Front Pharmacol."},{"issue":"7","key":"2024121020403990700_CIT0125","doi-asserted-by":"crossref","first-page":"e22284","DOI":"10.1371\/journal.pone.0022284","article-title":"The action mechanism of the Myc inhibitor termed Omomyc may give clues on how to target Myc for cancer therapy","volume":"6","author":"Savino","year":"2011","journal-title":"PLoS One."},{"issue":"484","key":"2024121020403990700_CIT0126","doi-asserted-by":"crossref","first-page":"eaar5012","DOI":"10.1126\/scitranslmed.aar5012","article-title":"Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy","volume":"11","author":"Beaulieu","year":"2019","journal-title":"Sci Transl Med."},{"issue":"5","key":"2024121020403990700_CIT0127","doi-asserted-by":"crossref","first-page":"e97285","DOI":"10.1371\/journal.pone.0097285","article-title":"Targeting of the MYCN protein with small molecule c-MYC inhibitors","volume":"9","author":"M\u00fcller","year":"2014","journal-title":"PLoS One."},{"issue":"1","key":"2024121020403990700_CIT0128","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s13046-022-02367-5","article-title":"The MYCN inhibitor BGA002 restores the retinoic acid response leading to differentiation or apoptosis by the mTOR block in MYCN-amplified neuroblastoma","volume":"41","author":"Lampis","year":"2022","journal-title":"J Exp Clin Cancer Res."},{"issue":"6","key":"2024121020403990700_CIT0129","doi-asserted-by":"crossref","first-page":"E1229","DOI":"10.1073\/pnas.1710901115","article-title":"MYCN-amplified neuroblastoma maintains an aggressive and undifferentiated phenotype by deregulation of estrogen and NGF signaling","volume":"115","author":"Dzieran","year":"2018","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"4","key":"2024121020403990700_CIT0130","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.celrep.2016.06.052","article-title":"Regulation of nuclear hormone receptors by MYCN-driven mirnas impacts neural differentiation and survival in neuroblastoma patients","volume":"16","author":"Ribeiro","year":"2016","journal-title":"Cell Rep"},{"issue":"4","key":"2024121020403990700_CIT0131","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1073\/pnas.0913517107","article-title":"MYCN-regulated microRNAs repress estrogen receptor-\u03b1 (ESR1) expression and neuronal differentiation in human neuroblastoma","volume":"107","author":"Lov\u00e9n","year":"2010","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"578770","key":"2024121020403990700_CIT0132","first-page":"1","article-title":"Histone deacetylases and histone deacetylase inhibitors in neuroblastoma","volume":"8","author":"Phimmachanh","year":"2020","journal-title":"Front Cell Dev Biol."},{"issue":"1","key":"2024121020403990700_CIT0133","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1186\/s12885-020-07008-8","article-title":"INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I\/II trial series: The combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies","volume":"20","author":"Van Tilburg","year":"2020","journal-title":"BMC Cancer"},{"issue":"12","key":"2024121020403990700_CIT0134","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.3390\/biomedicines11123251","article-title":"Histone H3 acetylation is involved in retinoid acid-induced neural differentiation through increasing mitochondrial function","volume":"11","author":"Zhang","year":"2023","journal-title":"Biomedicines"},{"issue":"2","key":"2024121020403990700_CIT0135","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1158\/0008-5472.CAN-22-1029","article-title":"Mitochondrial uncoupling induces epigenome remodeling and promotes differentiation in neuroblastoma","volume":"83","author":"Jiang","year":"2023","journal-title":"Cancer Res."},{"issue":"1","key":"2024121020403990700_CIT0136","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s13402-022-00739-9","article-title":"Targeting ARHGEF12 promotes neuroblastoma differentiation, MYCN degradation, and reduces tumorigenicity","volume":"46","author":"Yang","year":"2023","journal-title":"Cell Oncol (Dordr)"},{"issue":"8","key":"2024121020403990700_CIT0137","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1038\/s41416-020-0759-0","article-title":"Dual metabolic reprogramming by ONC201\/TIC10 and 2-Deoxyglucose induces energy depletion and synergistic anti-cancer activity in glioblastoma","volume":"122","author":"Pruss","year":"2020","journal-title":"Br J Cancer."},{"issue":"2","key":"2024121020403990700_CIT0138","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.3390\/ijms24021649","article-title":"ONC201 suppresses neuroblastoma growth by interrupting mitochondrial function and reactivating nuclear ATRX expression while decreasing MYCN","volume":"24","author":"Wu","year":"2023","journal-title":"Int J Mol Sci ."},{"issue":"1","key":"2024121020403990700_CIT0139","first-page":"vdac143","article-title":"Phase I dose escalation and expansion trial of single agent ONC201 in pediatric diffuse midline gliomas following radiotherapy","volume":"4","author":"Gardner","year":"2022","journal-title":"Neurooncol. Adv."},{"issue":"12 Pt 1","key":"2024121020403990700_CIT0140","first-page":"5914","article-title":"Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients","volume":"44","author":"Schulz","year":"1984","journal-title":"Cancer Res."},{"issue":"14","key":"2024121020403990700_CIT0141","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1056\/NEJMoa0911123","article-title":"Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma","volume":"363","author":"Yu","year":"2010","journal-title":"N Engl J Med."},{"issue":"12","key":"2024121020403990700_CIT0142","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/jamaoncol.2018.4005","article-title":"Humanized 3F8 Anti-GD2 monoclonal antibody dosing with granulocyte-macrophage colony-stimulating factor in patients with resistant neuroblastoma: a phase 1 clinical trial","volume":"4","author":"Kushner","year":"2018","journal-title":"JAMA Oncol"},{"issue":"21","key":"2024121020403990700_CIT0143","doi-asserted-by":"crossref","first-page":"6320","DOI":"10.1158\/1078-0432.CCR-19-1452","article-title":"A Phase II Trial of Hu14.18K322A in combination with induction chemotherapy in children with newly diagnosed high-risk neuroblastoma","volume":"25","author":"Furman","year":"2019","journal-title":"Clin Cancer Res."},{"issue":"3","key":"2024121020403990700_CIT0144","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1200\/JCO.20.01892","article-title":"Survival impact of anti-GD2 antibody response in a phase II ganglioside vaccine trial among patients with high-risk neuroblastoma with prior disease progression","volume":"39","author":"Cheung","year":"2020","journal-title":"J Clin Oncol."},{"issue":"2","key":"2024121020403990700_CIT0145","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1001\/jamaoncol.2022.5999","article-title":"Effect of oral \u03b2-glucan on antibody response to ganglioside vaccine in patients with high-risk neuroblastoma: a phase 2 randomized clinical trial","volume":"9","author":"Cheung","year":"2023","journal-title":"JAMA Oncol"},{"issue":"1","key":"2024121020403990700_CIT0146","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s13045-022-01383-4","article-title":"Phase 1 study of intraventricular 131I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies","volume":"15","author":"Kramer","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"108241","key":"2024121020403990700_CIT0147","first-page":"1","article-title":"Bispecific antibodies for the treatment of neuroblastoma","volume":"237","author":"Espinosa-Cotton","year":"2022","journal-title":"Pharmacol Ther."},{"issue":"5","key":"2024121020403990700_CIT0148","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/s41591-020-0844-1","article-title":"A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors","volume":"26","author":"Slyper","year":"2020","journal-title":"Nat Med."},{"issue":"4","key":"2024121020403990700_CIT0149","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/s00262-004-0603-z","article-title":"Expression of MHC class I, MHC class II, and cancer germline antigens in neuroblastoma","volume":"54","author":"W\u00f6lfl","year":"2005","journal-title":"Cancer Immunol Immunother"},{"issue":"2380","key":"2024121020403990700_CIT0150","first-page":"1","article-title":"CAR T Cell Therapy for Neuroblastoma","volume":"9","author":"Richards","year":"2018","journal-title":"Front Immunol."},{"key":"2024121020403990700_CIT0151","article-title":"GD2 specific CAR and interleukin-15 expressing autologous NKT cells to treat children with neuroblastoma (GINAKIT2)","author":"ClinicalTrials.gov. Bethesda (MD)","year":"2017"},{"key":"2024121020403990700_CIT0152","author":"ClinicalTrials.gov. Bethesda (MD)","year":"2017"},{"issue":"14","key":"2024121020403990700_CIT0153","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","article-title":"GD2-CART01 for relapsed or refractory high-risk neuroblastoma","volume":"388","author":"Del Bufalo","year":"2023","journal-title":"N Engl J Med."},{"issue":"3","key":"2024121020403990700_CIT0154","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ccell.2017.08.003","article-title":"Identification of GPC2 as an oncoprotein and candidate immunotherapeutic target in high-risk neuroblastoma","volume":"32","author":"Bosse","year":"2017","journal-title":"Cancer Cell"},{"issue":"6","key":"2024121020403990700_CIT0155","first-page":"1","article-title":"CAR T cells targeting tumor-associated exons of glypican 2 regress neuroblastoma in mice","volume":"2","author":"Li","year":"2021","journal-title":"Cell Rep Med"},{"issue":"7988","key":"2024121020403990700_CIT0156","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/s41586-023-06706-0","article-title":"Targeting of intracellular oncoproteins with peptide-centric CARs","volume":"623","author":"Yarmarkovich","year":"2023","journal-title":"Nature."},{"issue":"1","key":"2024121020403990700_CIT0157","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/s41467-020-20785-x","article-title":"Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma","volume":"12","author":"Moghimi","year":"2021","journal-title":"Nat Commun."},{"issue":"19","key":"2024121020403990700_CIT0158","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1200\/JCO.20.00203","article-title":"Irinotecan, temozolomide, and dinutuximab with GM-CSF in children with refractory or relapsed neuroblastoma: a report from the children\u2019s oncology group","volume":"38","author":"Mody","year":"2020","journal-title":"J Clin Oncol."},{"issue":"4","key":"2024121020403990700_CIT0159","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(20)30023-1","article-title":"Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial","volume":"21","author":"Davis","year":"2020","journal-title":"Lancet Oncol."},{"key":"2024121020403990700_CIT0160","article-title":"Testing the combination of two immunotherapy drugs (Nivolumab and Ipilimumab) in children, adolescent, and young adult patients with relapsed\/refractory cancers that have an increased number of genetic changes, the 3ci study","author":"ClinicalTrials.gov. Bethesda (MD)","year":"2020"},{"key":"2024121020403990700_CIT0161","article-title":"Nivolumab with or without ipilimumab in treating younger patients with recurrent or refractory solid tumors or sarcomas","author":"ClinicalTrials.gov. Bethesda (MD)","year":"2014"},{"key":"2024121020403990700_CIT0162","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1038\/s43018-022-00427-5","article-title":"Mesenchymal and adrenergic cell lineage states in neuroblastoma possess distinct immunogenic phenotypes","volume":"3","author":"Sengupta","year":"2022","journal-title":"Nat Cancer"},{"issue":"56","key":"2024121020403990700_CIT0163","first-page":"1","article-title":"Natural killer cells and neuroblastoma: tumor recognition, escape mechanisms, and possible novel immunotherapeutic approaches","volume":"5","author":"Bottino","year":"2014","journal-title":"Front Immunol."},{"issue":"6","key":"2024121020403990700_CIT0164","doi-asserted-by":"crossref","first-page":"e1316439","DOI":"10.1080\/2162402X.2017.1316439","article-title":"MYCN is an immunosuppressive oncogene dampening the expression of ligands for NK-cell-activating receptors in human high-risk neuroblastoma","volume":"6","author":"Brandetti","year":"2017","journal-title":"Oncoimmunology"},{"issue":"8","key":"2024121020403990700_CIT0165","doi-asserted-by":"crossref","first-page":"e1461305","DOI":"10.1080\/2162402X.2018.1461305","article-title":"Adoptive immunotherapy with haploidentical natural killer cells and Anti-GD2 monoclonal antibody m3F8 for resistant neuroblastoma: results of a phase I study","volume":"7","author":"Modak","year":"2018","journal-title":"Oncoimmunology"},{"issue":"2","key":"2024121020403990700_CIT0166","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ccell.2023.12.008","article-title":"Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy","volume":"42","author":"Wienke","year":"2024","journal-title":"Cancer Cell"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noae152\/60129373\/noae152.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noae152\/60964134\/noae152.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noae152\/60964134\/noae152.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T16:38:49Z","timestamp":1733848729000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/26\/12\/2174\/7727375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,5]]},"references-count":166,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,8,5]]},"published-print":{"date-parts":[[2024,12,5]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noae152","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,8,5]]}}}